Skip to main content
Barry Reisberg, MD, Geriatrics, New York, NY, NYU Langone Hospitals

BarryReisbergMD

Geriatrics • New York, NY

Dementia, Clinical Pharmacology

Professor, Department of Psychiatry Clinical Dir Aging & Dementia Rsch Ctr Director of the Zachary and Elizabeth M. Fisher Alzheimer Disease Education and Research program NYU School of Medicine

Join to view full profile

Dr. Reisberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Reisberg's full profile

Already have an account?

  • Office

    Aging and Dementia Research Center, New York University School of Medicine
    145 East 32nd Street, Room 508
    New York, NY 10016
    Phone+1 212-263-8550
    Fax+1 212-263-6991
  • Is this information wrong?

Summary

  • Barry Reisberg, M.D. is a Professor of Psychiatry at NYU Langone Health and Adjunct Professor at the Centre for Studies in Aging, McGill University, Montreal, Canada. Dr. Reisberg has directed research which has significantly advanced current understanding and treatment of Alzheimer's disease (AD). He was the first to describe many of the most important symptoms of AD and the characteristic clinical course of AD. His staging tools are presently governmentally mandated measures throughout the U.S., and widely used worldwide.

    Dr. Reisberg’s work has been instrumental in the development of all major current pharmacological treatment modalities for AD, i.e., memantine, treatment for behavioral disturbances in dementia (e.g., risperidone), rivastigmine for mild to moderate dementia, and donepezil for severe dementia.

    Dr. Reisberg and his associates developed the concepts behind and coined the terminology, “mild cognitive impairment,” a now universally recognized entity. His descriptions of an even earlier clinically manifest stage - “subjective cognitive impairment,” are increasingly being recognized as the earliest manifestations of AD in seemingly normal persons. Dr. Reisberg’s description of the retrogenic neurodevelopmental process in AD and related dementias is also advancing a new science of AD management and providing new insights into AD etiopathogenesis. In a 2017 study, Dr. Reisberg, et al. have demonstrated that a comprehensive management program can provide 10 times the benefits of either current AD medications or traditional non-pharmacologic treatments.

    Dr. Reisberg has been the recipient of numerous awards for his pioneering research including a Lifetime Achievement Award for Research in Alzheimer’s disease. He is a Distinguished Life Fellow of the American Psychiatric Association. He has also served as President of the International Psychogeriatric Association, and is a Fellow of the American College of Neuropsychopharmacology.

Education & Training

  • New York Medical College (Metropolitan)
    New York Medical College (Metropolitan)Residency, Psychiatry, 1973 - 1975
  • Lincoln Medical and Mental Health Center
    Lincoln Medical and Mental Health CenterInternship, Transitional Year, 1972 - 1973
  • New York Medical College
    New York Medical CollegeClass of 1972
  • Brooklyn College
    Brooklyn CollegeBA, 1964 - 1968
  • Nasson College
    Nasson CollegeNo Degree, 1963

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1973 - 2023
  • American Board of Psychiatry and Neurology Psychiatry
  • American Board of Psychiatry and Neurology Geriatric Psychiatry

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2001-2016, 2020
  • Best Doctors in America, Woodward/White The Best Doctors in America
  • Jack Weinberg Memorial Award for Geriatric Psychiatry American Psychiatric Association, 2017
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Novel Alzheimer Disease Locus Located near the Gene Encoding Tau Protein  
    Jun, G., Ibrahim-Verbaas, C.A., Vronskaya, M., Lambert, J-C., Chung, J., Naj, A.C., Kunkle, B.W., Wang, L-S., Bis, J-C., Bellenguez, C., Harold, D., Lunetta, K.L., Des..., Molecular Psychiatry, 1/1/2015
  • Subjective Cognitive Decline in Older Adults: An Overview of Self-report Measures Used across 19 International Research Studies  
    Rabin, L.A., Smart, C.M., Crane, P.K., Amariglio, R.E., Berman, L.M., Boada, M., Buckley, R.F., Chetelat, G., Dubois, B., Ellis, K.A., Gifford, K.A., Jefferson, A.L, J..., Journal of Alzheimer's Disease, 1/1/2015
  • Rarity of the Alzheimer disease-protective APP A673T variant in the United States  
    335. Wang, L-S., Naj, A.C., Graham, R.R., Crane, P.K., Kunkle, B.W., Cruchaga, C., Gonzalez Murcia, J.D., Cannon-Albright, L., Baldwin, C.T., Zetterberg, H., Blennow, ..., JAMA Neurology, 2015
  • Join now to see all

Books/Book Chapters

  • Care Giving for Alzheimer's Disease: A Compassionate Guide for Clinicians and Loved Ones 
    Chapter: Foreword 
    Reisberg, B.Editors: Carson, V.B., Vanderhorst, K.J. and Koenig, H.G..Springer2015
  • An Oral History of Neuropsychopharmacology: The First Fifty Years: Peer Interviews 
    Page 385.0 - 401.0Reisberg, B.Editors: Thomas A. Ban (editor), Barry Blackwell (volume editor).American College of Neuropsychopharmacology, Brentwood, Tennessee2011
  • Heuristic Modeling of the Mental Progress of Persons with Normal Brain Aging, Subjective Cognitive Impairment, Mild Cognitive Impairment, Alzheimer's Disease, and Related Dementia Disorders. 
    Page 167.0 - 172.0Winkler, S., Auer, S., Affenzeller, M., Donabauer, Y., and Reisberg, B.Editors: Claudia Frydman, Francesco Longo, and Khalid Mekouar.Universidad de la Laguna2009
  • Join now to see all

Abstracts/Posters

  • Evidence for Affective Symptoms as an Early Manifestation of Cognitive Change
    Guillo-Benarous, F., Sidhu, J., Patel, P., Naqvi, S., Thu, M., Ghimire, S., Xu, J., and Reisberg, B., Neurodegenerative Diseases, 1/1/2015
  • Mock Trial of a Lawsuit Alleging Financial Fraud Against a 79 Year Old Woman by an Insurance Agent and an Insurance Company
    Stein, E.M., Finkel. S., Liptzin, B., Reisberg, B., The American Journal of Geriatric Psychiatry, 1/1/2014
  • Evaluation of Symptoms in Persons with Subjective Cognitive Impairment
    Guillo-Benarous, F., Vengassery, A., Ghimire, S., Xu, J., Torossian, C., and Reisberg, B., Alzheimer's & Dementia, 1/1/2014
  • Join now to see all

Lectures

  • Novel and Emerging Aspects of Brain Aging and Alzheimer's Disease: Part 1: "Subjective Cognitive Impairment (SCI), The Pre-MCI Stage of Alzheimer's Disease: Antecedent... 
    Iasi, Romania - 1/27/2012
  • "Subject Interview and Final Discussion," in "Workshop on Methodologies for Clinical Trials in Pre-MCI Persons with Subjective Cognitive Impairment (SCI)" 
    Toronto, Canada - 1/26/2011
  • Treatment of Alzheimer's Disease: Function," in "Alzheimer's Disease in Primary Care Settings 
    Paris, France. - 1/16/2011
  • Join now to see all

Other

  • BEHAVE-AD 
    Barry Reisberg, M.D.
    1/1/2008
  • Documental Alzheimer, directed by Eduardo Antoja 
    Fundacion Ala Caixa
    Barcelona, Spain - 1/1/2004
  • Clinical Experience with Ebixa in Moderate to Severe AD [via videoconference from New York, New York] 
    Ebixa Launch Symposium
    Thessalonika, Greece, 2003; Athens, Greece, 2003 - 1/1/2003
  • Join now to see all

Press Mentions

  • St. Luke’s Health-Memorial, Baylor College of Medicine Establish New Rural Health Residency Program
    St. Luke’s Health-Memorial, Baylor College of Medicine Establish New Rural Health Residency ProgramOctober 8th, 2022
  • How Alzheimer's Disease Progresses: From Diagnosis Through the 7 Stages
    How Alzheimer's Disease Progresses: From Diagnosis Through the 7 StagesAugust 22nd, 2022
  • 7 Stages of Alzheimer’s Disease…and Related Dementia
    7 Stages of Alzheimer’s Disease…and Related DementiaApril 9th, 2020
  • Join now to see all

Grant Support

  • Institutionalization of Alzheimer's disease patients: precipitating factors and effects of intervention and counselingAARP Andrus Foundation1984–Present
  • A proof of concept study fo the prevention of mild cognitive impairment and eventual Alzheimer's diseaseThe Stringer Foundation2011–2018
  • Clinical Researcher Development Fund of the New York University School of MedicineNew York University School of Medicine2013–2017
  • Alzheimer's Research under the direction of Barry Reisberg, M.D.The Louis J. Kay and June E. Kay Foundation2011–2017
  • Alzheimer's Research under the direction of Barry Reisberg, M.D. and Steven Ferris, Ph.D.The Hagedorn Fund2006–2017
  • The Zachary and Elizabeth M. Fisher Education and Resources Program at the New York University School of MedicineThe Zachary and Elizabeth M. Fisher Center for Alzheimer's Research Foundation2008–2016
  • Alzheimer's Disease Prevention and TreatmentThe Woodburne Foundation2008–2012
  • Clinical Core (And Smp)National Institute On Aging2010
  • Clinical CoreNational Institute On Aging2005–2009
  • Alzheimer's Research under the direction of Dr. Barry ReisbergThe Leonard Litwin Fund for Alzheimer's Disease Research2004–2009
  • Aging And Dementia Longitudinal Course Of SubgroupsNational Center For Research Resources2004–2008
  • The Zachary and Elizabeth M. Fisher Center for Alzheimer's Research FoundationZachary and Elizabeth M. Fisher Medical Foundation, in association with the U.S. DHHS Administration on Aging1998–2007
  • Aging And Dementia--Longitudinal Course Of SubgroupsNational Institute On Aging1997–2002
  • Core--ClinicalNational Institute On Aging1996–2002
  • Zachary and Elizabeth M. Fisher Alzheimer's Disease Education and Resources Program of the New York University Medical CenterZachary and Elizabeth M. Fisher Medical Foundation1995–1998
  • Core--ClinicalNational Institute On Aging1995–1996
  • Aging And Dementia--Longitudinal StudyNational Institute On Aging1995–1996
  • Behavioral And Psychotic Symptoms In Alzheimers DiseaseNational Institute On Aging1994
  • Aging And Dementia--Longitudinal StudyNational Institute On Aging1994
  • Non-Pharmacologic Modifications Of Behavior In ADNational Institute On Aging1992–1994
  • Core--Clinical Assessment And TrackingNational Institute On Aging1990–1994
  • Aging And Dementia: Longitudinal Course Of SubgroupsNational Institute On Aging1993
  • Behavioral And Psychotic Symptoms In Alzheimer'S DiseaseNational Institute On Aging1990–1993
  • Aging And Dementia--Longitudinal Course Of SubgroupsNational Institute On Aging1992
  • Aging And Dementia: Longitudinal Course Of SubgroupsNational Institute On Aging1987–1991
  • Phenomenology and Pharmacologic Remediation of Psychotic and Psychosis-like Symptomatology in Alzheimer's DiseaseBeckman Research Institute of the City of Hope and the Hurd Foundation1984–1985
  • Naloxone treatment of primary degenerative dementiaThe Nina M. Werblow Charitable Trust1982–1984

Committees

  • Medical and Scientific Advisory Panel, Alzheimer's Disease International 1997 - Present
  • Scientific Advisory Board, Maria Wolff Foundation, Madrid, Spain 2014 - 2014
  • Steering Committee, New York University Medical Center, Comprehensive Center on Brain Aging 2012 - 2013
  • Awards Selection Committee, Annual Research Day, New York University Medical Center, The Comprehensive Center on Brain Aging and Silberstein Alzheimer's Institute 2012 - 2013
  • Competition Committee for the position of Director of the Council of Doctoral Studies, Romania Education Ministry, University of Medicine and Pharmacy, Gr. T. Popa, Iasi 2012 - 2012
  • Center of Excellence on Brain Aging Seed Grant Review Committee, New Yok University Langone Medical Center, Center of Excellence on Brain Aging, Office of Science and Research 2012 - 2012
  • Global Scientific Committee, Wisdem: Understanding Dementia, Improving Quality of Life 2011 - 2011
  • Pilot Study Review Committee, New York University School of Medicine, Alzheimer's Disease Center 2011 - 2011
  • Director, Scientific Colloquium Series, New York University School of Medicine, Alzheimer's Disease Center 2010 - 2011
  • Steering Committee, New York University School of Medicine, Center of Excellence on Brain Aging 2009 - 2012
  • International Scientifice Committee, 8th Congress of the International Society for the Amelioration of the Quality of Life, Delphi, Greece 2009 - 2010
  • Chairman, Prevention Working Group, Alzheimer's Disease International 2008 - 2017
  • Appointments and Promotions Committee, New York University School of Medicine, Department of Psychiatry 2008 - 2013
  • Chairman, Retrospective Review of Testamentary Capacity Subgroup of the Task Force on Testametary Capacity, International Psychogeriatric Association 2008 - 2011
  • International Advisory Board, 25th International Conference of Alzheimer's Disease International, Thessaloniki, Greece 2008 - 2010
  • Scientific Program Committee, 23rd Alzheimer's Disease International Conference, Caracus, Venezuela 2006 - 2007
  • Advisory Committee, IV Neuroforum Dementia Conference, Barcelona, Spain 2006 - 2006
  • Advisory Committee, Neuroforum Dementia, Barcelona, Spain 2005 - 2005
  • Scientific Program Committee, 12th Congress, International Psychogeriatric Association 2005 - 2005
  • International Scientific Committee, 3rd International Congress on the Improvement of the Quality of Life in Dementia, Epilepsy, and MS, Alexandria, Egypt 2004 - 2005
  • Advisory Committee, Neuroforum Dementia, Barcelona, Spain 2003 - 2004
  • Task Force on Dementia, World Federation of Societies of Biological Psychiatry 2002 - 2017
  • Advisory Board, Morbus Alzheimer Society, Bad Ischl, Austria 2002 - 2017
  • Scientific Executive Committee, New York University School of Medicine, William and Silvia Silberstein Institute for Aging and Dementia 2002 - 2009
  • Professional Advisory Committee, Alzheimer's Disease and Related Disorders Inc., New York City Chapter 2002 - 2006
  • Scientific Program Committee, 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA 2002 - 2004
  • Board of Directors, New York University School of Medicine, William and Silvia Silberstein Institute for Aging and Dementia 2001 - 2006
  • International Consultant, Alzheimer's Disease and Dementia Initiative, Invitational Planning Symposium, Government of Alberta, Department of Health and Wellness, Edmonton, Alberta, Canada 2001 - 2001
  • Ethics Committee, International College of Geriatric Psychopharmacology 2001 - 2001
  • Organizing Committee, 11th International Psychogeriatric Association International Congress 2001 - 2001
  • Co-Convener, International Conference, From Retrogenesis to Cognitive Intervention in Alzheimer's Disease, Barcelona, Spain 2001 - 2001
  • International Scientific Advisory Committee, 2nd Bologna International Meeting on Cognitive, Affective and Behavioral Disorders in the Elderly, Bologna, Italy 2000 - 2000
  • Congress Scientific Committee, Regional Congress of Biological Psychiatry, Istanbul, 2000, Istanbul, Turkey 2000 - 2000
  • Scientific Advisory Council, World Alzheimer Congress 2000 - 2000
  • Consultant, Psychopharmacologic Drugs Advisory Committee, Food and Drug Adminstration (USA) 2000 - 2000
  • Research Committee, New York University School of Medicine, Department of Psychiatry 1999 - 2008
  • Past President, International Psychogeriatric Association 1999 - 2001
  • Chairman, Publications Committee, International Psychogeriatric Association 1999 - 2001
  • Work Group on Women and Alzheimer's Disease, Ronald and Nancy Reagan Research Institute, Alzheimer's Association 1998 - 1998
  • President, International Psychogeriatric Association 1997 - 1999
  • Chairman, International Working Group of Harmonization of Dementia Drug Guidelines, Clinical Global Committee 1995 - 2005
  • President-Elect, Internatinoal Psychogeriatric Association 1995 - 1997
  • International Research Advisory Board, WHO Project on Development of Methodologies for early Diagnosis, Prevention and Treatment of Alzheimer's Disease 1995 - 1995
  • Chairman, International ADL Project sponsored by Bayer AG 1993 - 2001
  • Medical and Scientific Advisory Board, Alzheimer's Association (USA) 1993 - 1997
  • Treasurer, Internatinoal Psychogeriatric Association 1993 - 1995
  • Research Committee, American Association for Geriatric Psychiatry 1992 - 1999
  • Board of Directors, American Association for Geriatric Psychiatry 1992 - 1996
  • Secretary, American Association for Geriatric Psychiatry 1991 - 1992
  • Executive Committee, New York University School of Medicine, NYU Alzheimer's Disease Center 1990 - 2017
  • National Institutes of Health Reviewers Reserve, National Institutes of Health 1990 - 1994
  • Contributor, Delirium, Dementia and Amnestic and other Cognitive Disorder Advisor, Work Group, Diagnostic and Statistic Manual of Mental Disorders: 4th Edition (DSM-IV), American Psychiatric Association 1990 - 1994
  • Board of Directors, American Aging Association 1990 - 1992
  • Chairman, Pharmacy and Therapeutics Committee, International Psychogeriatric Association 1989 - 2003
  • Ad Hoc FDA Dementia Assessment Task Force, Division of Neuropsychopharmacological Drug Products Peripheral and Central Nervous System Advisory Committee, Food and Drug Administration (USA) 1989 - 1989
  • International Scientific Advisory Committee, International Conferences on Alzheimer's Disease and Related Disorders 1988 - 2006
  • Chairman, Research Awards Committee, Internatinoal Psychogeriatric Association 1988 - 2003
  • Professional Advisory Committee, New York Department of Housing Preservation and Development 1987 - 1987
  • Grant Reviewer for the NIH, Human Development and Aging Study Section, Division of Research Grants, National Institutes of Health 1986 - 1990
  • Research Advisory Board, National Center for Homecare, Education and Research 1986 - 1988
  • American Psychiatric Association Delegate, The 1981 White House Conference on Aging to 1986: a Mid-Decade Review 1986 - 1986
  • Board of Directors, Internatinoal Psychogeriatric Association 1985 - 1993
  • Research Advisory Board, Visiting Nurse Service of New York 1985 - 1985
  • Institute on Alzheimer's Disease and Related Disorders, New York Academy of Medicine and New York State Health Planning Commission 1984 - 1987
  • Advisory Board, Alzheimer's Disease Center, New York City Department for the Aging 1984 - 1986
  • Program Committee, American Association for Geriatric Psychiatry 1984 - 1985
  • Chairman, Workgroup on Drugs and Cerebral Function, World Health Organization 1984 - 1984
  • Examiner, American Board of Psychiatry and Neurology 1983 - 1983
  • Planning Committee, Mayoral Conference on Alzheimer's Disease, New York City Department for the Aging 1983 - 1983
  • Task Force to Develop a Curriculum in Geriatric Psychiatry, American Psychiatric Association 1982 - 1983
  • Chairman, Awards Committe, American Association for Geriatric Psychiatry 1980 - 1981

Professional Memberships

  • American Association for the Advancement of Science
    Member
  • American Association for Geriatric Psychiatry
    Member
  • American College of Neuropsychopharmacology
    Fellow
  • American Medical Association
    Member
  • American Psychiatric Association
    Distinguished Life Fellow
  • British Brain Research Association
    Honorary Member
  • European Brain and Behavior Society
    Honorary Member
  • International Psychogeriatric Association
    Past President
  • Society for Neuroscience
    Member
  • World Psychiatric Association Section on Old Age Psychiatry
    Member

Hospital Affiliations

External Links

Dr. Barry Reisberg, Dr. Barry Reisberg, MD, Dr. B Reisberg